Generic Name and Formulations:
Oxybutynin 3.9mg/day; transdermal patch.
Indications for OXYTROL:
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Apply to clean, dry area on the abdomen, hip, or buttock. 1 patch twice weekly (every 3–4 days). Rotate application sites.
Urinary or gastric retention, uncontrolled narrow-angle glaucoma; or patients at risk for these.
Bladder outflow or GI obstruction. Hepatic or renal impairment. Ulcerative colitis. Intestinal atony. Hiatus hernia/GERD. Discontinue if skin hypersensitivity or angioedema develops; consider discontinuing if anticholinergic CNS effects occur. Avoid in myasthenia gravis; discontinue if symptoms occur. Exposure to high environmental temperature. Pregnancy. Nursing mothers.
CNS depression potentiated by alcohol, other CNS depressants. Additive effects with other anticholinergics. May affect GI absorption of other drugs. Caution with drugs that cause or exacerbate esophagitis (eg, bisphosphonates).
Local reactions, anticholinergic effects (eg, dry mouth, constipation, dizziness, abnormal vision, somnolence, confusion, hallucinations), headache, diarrhea, rash.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline